Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2−/tm1Som), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels, prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal function.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Koulen, P. et al. Nat. Cell Biol. 4, 191–197 (2002).
Nauli, S.M. et al. Nat. Genet. 33, 129–137 (2003).
Qian, Q. et al. Hum. Mol. Genet. 12, 1875–1880 (2003).
Chabardes, D., Imbert-Teboul, M. & Elalouf, J.M. Cell. Signal. 11, 651–663 (1999).
Wallace, D.P., Rome, L.A., Sullivan, L.P. & Grantham, J.J. Am. J. Physiol. Renal Physiol. 280, F1019–F1029 (2001).
Ye, M. & Grantham, J. N. Engl. J. Med. 329, 310–313 (1993).
Yamaguchi, T. et al. Kidney Int. 57, 1460–1471 (2000).
Gattone, V.H., Wang, X., Harris, P.C. & Torres, V.E. Nat. Med. 9, 1323–1326 (2003).
Wu, G. et al. Cell 93, 177–188 (1998).
Verani, R.R. & Silva, F.G. Mod. Pathol. 1, 457–463 (1988).
Gabow, P. et al. Kidney Int. 35, 675–680 (1989).
Sweeney, W.E., Jr. et al. Am. J. Physiol. Cell Physiol. 281, C1695–C1705 (2001).
Yamaguchi, T., Wallace, D.P., Grantham, J.J. & Calvet, J.P. J. Am. Soc. Nephrol. 13, 105A (2002).
Thibonnier, M., Coles, P., Thibonnier, A. & Shoham, M. Annu. Rev. Pharmacol. Toxicol. 41, 175–202 (2001).
This work was supported by National Institutes of Health grant DK44863 (V.E.T.) and by a grant from the Polycystic Kidney Disease Foundation (V.H.G.). OPC31260 was a gift from Otsuka Pharmaceutical. Technical assistance was provided by Ming Li.
V.H.G. is listed as the inventor on the US patent, held by the University of Kansas Medical Center, entitled, “Treatment of polycystic kidney disease using vasopressin V2 receptor antagonists.”
About this article
Synergistic Genetic Interactions between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models
Journal of the American Society of Nephrology (2019)
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease
Kidney International (2019)
A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease
American Journal of Physiology-Renal Physiology (2019)
The Lancet (2019)
Current Biology (2019)